Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Abschlussarbeit Buch |
| Sprache: | English |
| Veröffentlicht: |
Aachen
Apprimus Verlag
2023
|
| Ausgabe: | 1. Auflage |
| Schriftenreihe: | Applied microbiology
Volume 29 |
| Schlagworte: | |
| Online-Zugang: | kostenfrei Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | 160 Seiten Illustrationen, Diagramme 21 cm, 250 g |
| ISBN: | 9783985551354 3985551359 |
| DOI: | 10.18154/RWTH-2023-00622 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV049035447 | ||
| 003 | DE-604 | ||
| 005 | 20230706 | ||
| 007 | t | ||
| 008 | 230705s2023 gw a||| m||| 00||| eng d | ||
| 015 | |a 23,N04 |2 dnb | ||
| 015 | |a 23,A19 |2 dnb | ||
| 015 | |a 23,H06 |2 dnb | ||
| 016 | 7 | |a 1278363092 |2 DE-101 | |
| 020 | |a 9783985551354 |c Broschur : EUR 49.00 (DE), EUR 50.40 (AT) |9 978-3-98555-135-4 | ||
| 020 | |a 3985551359 |9 3-98555-135-9 | ||
| 024 | 3 | |a 9783985551354 | |
| 035 | |a (OCoLC)1366294730 | ||
| 035 | |a (DE-599)DNB1278363092 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-NW | ||
| 049 | |a DE-29T | ||
| 084 | |8 1\p |a 610 |2 23sdnb | ||
| 084 | |8 2\p |a 570 |2 23sdnb | ||
| 100 | 1 | |a Baier, Vanessa |d 1989- |e Verfasser |0 (DE-588)1279555629 |4 aut | |
| 245 | 1 | 0 | |a Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions |c Vanessa Baier |
| 250 | |a 1. Auflage | ||
| 264 | 1 | |a Aachen |b Apprimus Verlag |c 2023 | |
| 300 | |a 160 Seiten |b Illustrationen, Diagramme |c 21 cm, 250 g | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Applied microbiology |v Volume 29 | |
| 502 | |b Dissertation |c RWTH Aachen University |d 2022 | ||
| 650 | 0 | 7 | |a Nebenwirkung |0 (DE-588)4317914-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Risikoanalyse |0 (DE-588)4137042-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakokinetik |0 (DE-588)4115557-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Modellierung |0 (DE-588)4170297-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Hepatose |0 (DE-588)4159555-5 |2 gnd |9 rswk-swf |
| 653 | |a Mikrobiologie | ||
| 653 | |a adverse drug reactions | ||
| 653 | |a microbiology | ||
| 653 | |a pharmacokinetic model | ||
| 655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
| 689 | 0 | 0 | |a Pharmakokinetik |0 (DE-588)4115557-9 |D s |
| 689 | 0 | 1 | |a Modellierung |0 (DE-588)4170297-9 |D s |
| 689 | 0 | 2 | |a Nebenwirkung |0 (DE-588)4317914-9 |D s |
| 689 | 0 | 3 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 0 | 4 | |a Hepatose |0 (DE-588)4159555-5 |D s |
| 689 | 0 | 5 | |a Risikoanalyse |0 (DE-588)4137042-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 710 | 2 | |a Apprimus Verlag |0 (DE-588)1068101474 |4 pbl | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, PDF |o https://doi.org/10.18154/RWTH-2023-00622 |
| 776 | 0 | 8 | |i Erscheint auch als |a Baier, Vanessa, 1989- |t Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions |d Aachen : Universitätsbibliothek der RWTH Aachen, 2023 |h Online-Ressource |n Online-Ausgabe |
| 830 | 0 | |a Applied microbiology |v Volume 29 |w (DE-604)BV042644516 |9 29 | |
| 856 | 4 | 1 | |u https://doi.org/10.18154/RWTH-2023-00622 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 2 | |m B:DE-101 |q application/pdf |u https://d-nb.info/1278363092/04 |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034298081&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 912 | |a ebook | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-034298081 | ||
| 883 | 2 | |8 1\p |a dnb |d 20230503 |q DE-101 |u https://d-nb.info/provenance/plan#dnb | |
| 883 | 2 | |8 2\p |a dnb |d 20230503 |q DE-101 |u https://d-nb.info/provenance/plan#dnb | |
Datensatz im Suchindex
| _version_ | 1804185324189908992 |
|---|---|
| adam_text | CONTENTS
EIDESSTATTLICHE
ERKLARUNG
......................................................................................................................
I
FUNDING
...................................................................................................................................................
III
ACKNOWLEDGEMENTS
................................................................................................................................
ABSTRACT
.................................................................................................................................................VII
ZUSAMMENFASSUNG
...............................................................................................................................
LIST
OF
FIGURES
......................................................................................................................................
XIII
LIST
OF
TABLES
.........................................................................................................................................
XV
LIST
OF
ABBREVIATIONS
.........................................................................................................................XVII
GENERAL
INTRODUCTION
.........................................................................................................................
19
PART
I:
BACKGROUND
...............................................................................................................................
25
1
D
RUG
-
INDUCED
ADVERSE
REACTIONS
......................................................................................................................
27
2
D
RUG
-
INDUCED
LIVER
INJURY
..................................................................................................................................
31
3
P
HARMACOKINETICS
................................................................................................................................................
33
4
P
HARMACOGENOMICS
..............................................................................................................................................
36
5
P
HARMACODYNAMICS
..............................................................................................................................................
37
6
C
OMPUTATIONAL
MODELLING
IN
PHARMACOMETRICS
...........................................................................................
39
6.1
PBPK
MODELLING
...............................................................................................................................................
40
6.2
POPULATION
PBPK
MODELLING
............................................................................................................................
43
6.3
PD
AND
QSP
MODELLING
....................................................................................................................................
43
PART
II:
MATERIALS
&
METHODS
.......
...................................................................................................
45
7
SOFTWARE
...............................................................................................................................................................
47
8
M
ATERIALSAND
M
ETHODS
USED
IN
C
HAPTER
11
..................................................................................................
47
8.1
MODEL
BUILDING
................................................................................................................................................
47
8.2
COMPETITIVE
INHIBITION
OF
BSEP
TRANSPORT
BY
CYCLOSPORINE
A
....................................................................
48
8.3
OBSERVED
DATA
................................................................................................................................................
49
8.4
DATA
NORMALISATION
.........................................................................................................................................
49
8.5
GOODNESS
OF
FIT
...............................................................................................................................................
49
9
M
ATERIALS
AND
M
ETHODS
USED
IN
C
HAPTER
12
..................................................................................................
50
9.1
DRUG-SPECIFIC
PBPK
MODELS
............................................................................................................................
50
9.2
MODEL-BASED
IN
VITRO
ASSAY
............................................................................................................................
50
9.3
INTEGRATION
OF
EXPRESSION
DATA
INTO
THE
PBBA
MODEL
..................................................................................50
9.4
POPULATION
SIMULATIONS
..................................................................................................................................
51
9.5
CHOLESTATIC
POTENTIAL
.......................................................................................................................................51
10
M
ATERIALSAND
M
ETHODS
USED
IN
C
HAPTER
13
................................................................................................
51
10.1
PBPK
MODEL
BUILDING
....................................................................................................................................
51
10.2
LITERATURE
PKDATA
.........................................................................................................................................
51
10.3
VIRTUAL
POPULATIONS
........................................................................................................................................
53
CONTENTS
PART
III
:
RESULTS
......................................................................................................................................
55
11
A
P
HYSIOLOGY
-B
ASED
M
ODEL
OF
H
UMAN
B
ILE
A
CID
M
ETABOLISM
FOR
P
REDICTING
B
ILE
A
CID
T
ISSUE
L
EVELS
AFTER
D
RUG
A
DMINISTRATION
IN
H
EALTHY
S
UBJECTSAND
BRIC
T
YPE
2
P
ATIENTS
...................................
57
11.1
INTRODUCTION
....................................................................................................................................................
58
11.2
RESULTS
.............................................................................................................................................................60
11.3
DISCUSSION
AND
CONCLUSION
............................................................................................................................
65
12
A
M
ODEL
-B
ASED
W
ORKFLOW
TO
B
ENCHMARK
THE
C
LINICAL
C
HOLESTASIS
R
ISK
OF
D
RUGS
.............................
69
12.1
INTRODUCTION
....................................................................................................................................................70
12.2
RESULTS
.............................................................................................................................................................
70
12.3
DISCUSSION
.......................................................................................................................................................
77
13
PBPK
GUIDED
ASSESSMENT
OF
A
LIVER
FUNCTION
TEST
.......................................................................................
79
13.1
INTRODUCTION
....................................................................................................................................................
80
13.2
RESULTS
.............................................................................................................................................................81
13.3
DISCUSSION
.......................................................................................................................................................
95
GENERAL
CONCLUSION
AND
OUTLOOK
.....................................................................................................
99
REFERENCES
...........................................................................................................................................
103
PART
IV:
APPENDICES
...........................................................................................................................
121
APPENDIX
A
...........................................................................................................................................
123
A.1
M
ETHODS
.........................................................................................................................................................
123
A.1.1
BUILD
A
BASIC
PBPK
MODEL
FOR
GCDCA
IN
PK-SIM
...................................................................................
124
A.1.2
EXTEND
THE
PBPK
MODEL
FOR
GCDCA
IN
MOBI
.........................................................................................
125
A.2
F
IGURES
.............................................................................................................................................................
126
A.3
T
ABLES
..............................................................................................................................................................
126
APPENDIX
B
...........................................................................................................................................
127
B.1
M
ETHODS
.........................................................................................................................................................
127
B.1.1
PBPK-ASSISTED
LIVER
SPHEROID
IN
VITRO
ASSAY
...........................................................................................
127
B.1.2
CLINICAL
DATA
..............................................................................................................................................
127
B.1.3
TRANSCRIPTOME
ANALYSIS
...........................................................................................................................
128
B.2
F
IGURES
............................................................................................................................................................
129
B.3
T
ABLES
.............................................................................................................................................................
140
APPENDIX
C
...........................................................................................................................................
145
C.1
F
IGURES
............................................................................................................................................................
145
C.2
T
ABLES
.............................................................................................................................................................
149
APPENDIX
D
.........................................................................................................................................
157
D.1
C
URRICULUM
V
ITAE
..........................................................................................................................................
157
D.2
P
UBLICATIONS
....................................................................................................................................................
159
|
| adam_txt |
CONTENTS
EIDESSTATTLICHE
ERKLARUNG
.
I
FUNDING
.
III
ACKNOWLEDGEMENTS
.
ABSTRACT
.VII
ZUSAMMENFASSUNG
.
LIST
OF
FIGURES
.
XIII
LIST
OF
TABLES
.
XV
LIST
OF
ABBREVIATIONS
.XVII
GENERAL
INTRODUCTION
.
19
PART
I:
BACKGROUND
.
25
1
D
RUG
-
INDUCED
ADVERSE
REACTIONS
.
27
2
D
RUG
-
INDUCED
LIVER
INJURY
.
31
3
P
HARMACOKINETICS
.
33
4
P
HARMACOGENOMICS
.
36
5
P
HARMACODYNAMICS
.
37
6
C
OMPUTATIONAL
MODELLING
IN
PHARMACOMETRICS
.
39
6.1
PBPK
MODELLING
.
40
6.2
POPULATION
PBPK
MODELLING
.
43
6.3
PD
AND
QSP
MODELLING
.
43
PART
II:
MATERIALS
&
METHODS
.
.
45
7
SOFTWARE
.
47
8
M
ATERIALSAND
M
ETHODS
USED
IN
C
HAPTER
11
.
47
8.1
MODEL
BUILDING
.
47
8.2
COMPETITIVE
INHIBITION
OF
BSEP
TRANSPORT
BY
CYCLOSPORINE
A
.
48
8.3
OBSERVED
DATA
.
49
8.4
DATA
NORMALISATION
.
49
8.5
GOODNESS
OF
FIT
.
49
9
M
ATERIALS
AND
M
ETHODS
USED
IN
C
HAPTER
12
.
50
9.1
DRUG-SPECIFIC
PBPK
MODELS
.
50
9.2
MODEL-BASED
IN
VITRO
ASSAY
.
50
9.3
INTEGRATION
OF
EXPRESSION
DATA
INTO
THE
PBBA
MODEL
.50
9.4
POPULATION
SIMULATIONS
.
51
9.5
CHOLESTATIC
POTENTIAL
.51
10
M
ATERIALSAND
M
ETHODS
USED
IN
C
HAPTER
13
.
51
10.1
PBPK
MODEL
BUILDING
.
51
10.2
LITERATURE
PKDATA
.
51
10.3
VIRTUAL
POPULATIONS
.
53
CONTENTS
PART
III
:
RESULTS
.
55
11
A
P
HYSIOLOGY
-B
ASED
M
ODEL
OF
H
UMAN
B
ILE
A
CID
M
ETABOLISM
FOR
P
REDICTING
B
ILE
A
CID
T
ISSUE
L
EVELS
AFTER
D
RUG
A
DMINISTRATION
IN
H
EALTHY
S
UBJECTSAND
BRIC
T
YPE
2
P
ATIENTS
.
57
11.1
INTRODUCTION
.
58
11.2
RESULTS
.60
11.3
DISCUSSION
AND
CONCLUSION
.
65
12
A
M
ODEL
-B
ASED
W
ORKFLOW
TO
B
ENCHMARK
THE
C
LINICAL
C
HOLESTASIS
R
ISK
OF
D
RUGS
.
69
12.1
INTRODUCTION
.70
12.2
RESULTS
.
70
12.3
DISCUSSION
.
77
13
PBPK
GUIDED
ASSESSMENT
OF
A
LIVER
FUNCTION
TEST
.
79
13.1
INTRODUCTION
.
80
13.2
RESULTS
.81
13.3
DISCUSSION
.
95
GENERAL
CONCLUSION
AND
OUTLOOK
.
99
REFERENCES
.
103
PART
IV:
APPENDICES
.
121
APPENDIX
A
.
123
A.1
M
ETHODS
.
123
A.1.1
BUILD
A
BASIC
PBPK
MODEL
FOR
GCDCA
IN
PK-SIM
.
124
A.1.2
EXTEND
THE
PBPK
MODEL
FOR
GCDCA
IN
MOBI
.
125
A.2
F
IGURES
.
126
A.3
T
ABLES
.
126
APPENDIX
B
.
127
B.1
M
ETHODS
.
127
B.1.1
PBPK-ASSISTED
LIVER
SPHEROID
IN
VITRO
ASSAY
.
127
B.1.2
CLINICAL
DATA
.
127
B.1.3
TRANSCRIPTOME
ANALYSIS
.
128
B.2
F
IGURES
.
129
B.3
T
ABLES
.
140
APPENDIX
C
.
145
C.1
F
IGURES
.
145
C.2
T
ABLES
.
149
APPENDIX
D
.
157
D.1
C
URRICULUM
V
ITAE
.
157
D.2
P
UBLICATIONS
.
159 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Baier, Vanessa 1989- |
| author_GND | (DE-588)1279555629 |
| author_facet | Baier, Vanessa 1989- |
| author_role | aut |
| author_sort | Baier, Vanessa 1989- |
| author_variant | v b vb |
| building | Verbundindex |
| bvnumber | BV049035447 |
| collection | ebook |
| ctrlnum | (OCoLC)1366294730 (DE-599)DNB1278363092 |
| doi_str_mv | 10.18154/RWTH-2023-00622 |
| edition | 1. Auflage |
| format | Thesis Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03282nam a2200733 cb4500</leader><controlfield tag="001">BV049035447</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20230706 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">230705s2023 gw a||| m||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">23,N04</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">23,A19</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">23,H06</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1278363092</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783985551354</subfield><subfield code="c">Broschur : EUR 49.00 (DE), EUR 50.40 (AT)</subfield><subfield code="9">978-3-98555-135-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3985551359</subfield><subfield code="9">3-98555-135-9</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783985551354</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1366294730</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1278363092</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-NW</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29T</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">1\p</subfield><subfield code="a">610</subfield><subfield code="2">23sdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">2\p</subfield><subfield code="a">570</subfield><subfield code="2">23sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Baier, Vanessa</subfield><subfield code="d">1989-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1279555629</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions</subfield><subfield code="c">Vanessa Baier</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. Auflage</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Aachen</subfield><subfield code="b">Apprimus Verlag</subfield><subfield code="c">2023</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">160 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield><subfield code="c">21 cm, 250 g</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Applied microbiology</subfield><subfield code="v">Volume 29</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="b">Dissertation</subfield><subfield code="c">RWTH Aachen University</subfield><subfield code="d">2022</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Nebenwirkung</subfield><subfield code="0">(DE-588)4317914-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Risikoanalyse</subfield><subfield code="0">(DE-588)4137042-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakokinetik</subfield><subfield code="0">(DE-588)4115557-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Modellierung</subfield><subfield code="0">(DE-588)4170297-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Hepatose</subfield><subfield code="0">(DE-588)4159555-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Mikrobiologie</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adverse drug reactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microbiology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmacokinetic model</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Pharmakokinetik</subfield><subfield code="0">(DE-588)4115557-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Modellierung</subfield><subfield code="0">(DE-588)4170297-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Nebenwirkung</subfield><subfield code="0">(DE-588)4317914-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="4"><subfield code="a">Hepatose</subfield><subfield code="0">(DE-588)4159555-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="5"><subfield code="a">Risikoanalyse</subfield><subfield code="0">(DE-588)4137042-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Apprimus Verlag</subfield><subfield code="0">(DE-588)1068101474</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, PDF</subfield><subfield code="o">https://doi.org/10.18154/RWTH-2023-00622</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="a">Baier, Vanessa, 1989-</subfield><subfield code="t">Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions</subfield><subfield code="d">Aachen : Universitätsbibliothek der RWTH Aachen, 2023</subfield><subfield code="h">Online-Ressource</subfield><subfield code="n">Online-Ausgabe</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Applied microbiology</subfield><subfield code="v">Volume 29</subfield><subfield code="w">(DE-604)BV042644516</subfield><subfield code="9">29</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://doi.org/10.18154/RWTH-2023-00622</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">B:DE-101</subfield><subfield code="q">application/pdf</subfield><subfield code="u">https://d-nb.info/1278363092/04</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034298081&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034298081</subfield></datafield><datafield tag="883" ind1="2" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">dnb</subfield><subfield code="d">20230503</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#dnb</subfield></datafield><datafield tag="883" ind1="2" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">dnb</subfield><subfield code="d">20230503</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#dnb</subfield></datafield></record></collection> |
| genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
| genre_facet | Hochschulschrift |
| id | DE-604.BV049035447 |
| illustrated | Illustrated |
| index_date | 2024-07-03T22:17:35Z |
| indexdate | 2024-07-10T09:53:25Z |
| institution | BVB |
| institution_GND | (DE-588)1068101474 |
| isbn | 9783985551354 3985551359 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034298081 |
| oclc_num | 1366294730 |
| open_access_boolean | 1 |
| owner | DE-29T |
| owner_facet | DE-29T |
| physical | 160 Seiten Illustrationen, Diagramme 21 cm, 250 g |
| psigel | ebook |
| publishDate | 2023 |
| publishDateSearch | 2023 |
| publishDateSort | 2023 |
| publisher | Apprimus Verlag |
| record_format | marc |
| series | Applied microbiology |
| series2 | Applied microbiology |
| spelling | Baier, Vanessa 1989- Verfasser (DE-588)1279555629 aut Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions Vanessa Baier 1. Auflage Aachen Apprimus Verlag 2023 160 Seiten Illustrationen, Diagramme 21 cm, 250 g txt rdacontent n rdamedia nc rdacarrier Applied microbiology Volume 29 Dissertation RWTH Aachen University 2022 Nebenwirkung (DE-588)4317914-9 gnd rswk-swf Risikoanalyse (DE-588)4137042-9 gnd rswk-swf Pharmakokinetik (DE-588)4115557-9 gnd rswk-swf Arzneimittel (DE-588)4003115-9 gnd rswk-swf Modellierung (DE-588)4170297-9 gnd rswk-swf Hepatose (DE-588)4159555-5 gnd rswk-swf Mikrobiologie adverse drug reactions microbiology pharmacokinetic model (DE-588)4113937-9 Hochschulschrift gnd-content Pharmakokinetik (DE-588)4115557-9 s Modellierung (DE-588)4170297-9 s Nebenwirkung (DE-588)4317914-9 s Arzneimittel (DE-588)4003115-9 s Hepatose (DE-588)4159555-5 s Risikoanalyse (DE-588)4137042-9 s DE-604 Apprimus Verlag (DE-588)1068101474 pbl Erscheint auch als Online-Ausgabe, PDF https://doi.org/10.18154/RWTH-2023-00622 Erscheint auch als Baier, Vanessa, 1989- Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions Aachen : Universitätsbibliothek der RWTH Aachen, 2023 Online-Ressource Online-Ausgabe Applied microbiology Volume 29 (DE-604)BV042644516 29 https://doi.org/10.18154/RWTH-2023-00622 Resolving-System kostenfrei Volltext B:DE-101 application/pdf https://d-nb.info/1278363092/04 Inhaltsverzeichnis DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034298081&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p dnb 20230503 DE-101 https://d-nb.info/provenance/plan#dnb 2\p dnb 20230503 DE-101 https://d-nb.info/provenance/plan#dnb |
| spellingShingle | Baier, Vanessa 1989- Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions Applied microbiology Nebenwirkung (DE-588)4317914-9 gnd Risikoanalyse (DE-588)4137042-9 gnd Pharmakokinetik (DE-588)4115557-9 gnd Arzneimittel (DE-588)4003115-9 gnd Modellierung (DE-588)4170297-9 gnd Hepatose (DE-588)4159555-5 gnd |
| subject_GND | (DE-588)4317914-9 (DE-588)4137042-9 (DE-588)4115557-9 (DE-588)4003115-9 (DE-588)4170297-9 (DE-588)4159555-5 (DE-588)4113937-9 |
| title | Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions |
| title_auth | Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions |
| title_exact_search | Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions |
| title_exact_search_txtP | Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions |
| title_full | Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions Vanessa Baier |
| title_fullStr | Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions Vanessa Baier |
| title_full_unstemmed | Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions Vanessa Baier |
| title_short | Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions |
| title_sort | physiologically based pharmacokinetic modelling for the prediction of adverse drug reactions |
| topic | Nebenwirkung (DE-588)4317914-9 gnd Risikoanalyse (DE-588)4137042-9 gnd Pharmakokinetik (DE-588)4115557-9 gnd Arzneimittel (DE-588)4003115-9 gnd Modellierung (DE-588)4170297-9 gnd Hepatose (DE-588)4159555-5 gnd |
| topic_facet | Nebenwirkung Risikoanalyse Pharmakokinetik Arzneimittel Modellierung Hepatose Hochschulschrift |
| url | https://doi.org/10.18154/RWTH-2023-00622 https://d-nb.info/1278363092/04 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034298081&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV042644516 |
| work_keys_str_mv | AT baiervanessa physiologicallybasedpharmacokineticmodellingforthepredictionofadversedrugreactions AT apprimusverlag physiologicallybasedpharmacokineticmodellingforthepredictionofadversedrugreactions |